Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines as potent inhibitors of human 5-lipoxygenase.

Yu Zhou; Jun Liu; Mingyue Zheng; Shuli Zheng; Chunyi Jiang; Xiaomei Zhou; Dong Zhang; Jihui Zhao; Deju YE; Mingfang Zheng; Hualiang Jiang; Dongxiang Liu; Jian Cheng; Hong Liu

Return

Structural optimization and biological evaluation of 1,5-disubstituted pyrazole-3-carboxamines as potent inhibitors of human 5-lipoxygenase.

Author: Yu ZHOU ¹ ; Jun LIU ² ; Mingyue ZHENG ¹ ; Shuli ZHENG ³ ; Chunyi JIANG ¹ ; Xiaomei ZHOU ³ ; Dong ZHANG ¹ ; Jihui ZHAO ¹ ; Deju YE ¹ ; Mingfang ZHENG ¹ ; Hualiang JIANG ¹ ; Dongxiang LIU ¹ ; Jian CHENG ³ ; Hong LIU ¹
Author Information

1. CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
2. China Pharmaceutical University, Nanjing 210009, China.
3. Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience, Soochow University, Suzhou 215006, China.
Publication Type:Journal Article
Keywords: 5-LOX inhibitors; 5-Lipoxygenase; Benzo-fused heterocycle; Brain inflammation; In vivo; Ischemic incults; Leukotrienes-related diseases; Pyrazole derivatives
From: Acta Pharmaceutica Sinica B 2016;6(1):32-45
CountryChina
Language:English
Abstract: Human 5-lipoxygenase (5-LOX) is a well-validated drug target and its inhibitors are potential drugs for treating leukotriene-related disorders. Our previous work on structural optimization of the hit compound 2 from our in-house collection identified two lead compounds, 3a and 3b, exhibiting a potent inhibitory profile against 5-LOX with IC50 values less than 1 µmol/L in cell-based assays. Here, we further optimized these compounds to prepare a class of novel pyrazole derivatives by opening the fused-ring system. Several new compounds exhibited more potent inhibitory activity than the lead compounds against 5-LOX. In particular, compound 4e not only suppressed lipopolysaccharide-induced inflammation in brain inflammatory cells and protected neurons from oxidative toxicity, but also significantly decreased infarct damage in a mouse model of cerebral ischemia. Molecular docking analysis further confirmed the consistency of our theoretical results and experimental data. In conclusion, the excellent in vitro and in vivo inhibitory activities of these compounds against 5-LOX suggested that these novel chemical structures have a promising therapeutic potential to treat leukotriene-related disorders.